sorry, we can't preview this file
Supplementary Figures.docx (1.48 MB)
Supplementary Figures – Efficacy and Safety of First-Line Therapies in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
figureposted on 2022-02-21, 12:36 authored by Figshare Future Science GroupFigshare Future Science Group, Katrin Haeussler, Xuan Wang, Katherine B Winfree, Yulia D'yachkova, Sory Traore, Tarun Puri, Howard Thom, Christos Papagiannopoulos, Maria Nassim, Kaisa Taipale
Figure A1. Sensitivity analysis of PFS splitting the erlotinib and gefitinib node (random effects).
Figure A2. Subgroup analysis of PFS of treatments versus erlotinib/gefitinib in East Asian patients (random effects).
Figure A3. Subgroup analysis of PFS of treatments versus erlotinib/gefitinib in non-East Asian patients (random effects).